{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T13:45:56Z","timestamp":1697809556365},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T00:00:00Z","timestamp":1552608000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Amsterdam UMC"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1007\/s00117-019-0513-x","type":"journal-article","created":{"date-parts":[[2019,3,15]],"date-time":"2019-03-15T09:03:47Z","timestamp":1552640627000},"page":"348-356","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Autoimmunassoziierte Gallenwegserkrankungen"],"prefix":"10.1007","volume":"59","author":[{"given":"T.","family":"Herta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"Beuers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,15]]},"reference":[{"issue":"3","key":"513_CR1","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s00281-009-0164-5","volume":"31","author":"S Hohenester","year":"2009","unstructured":"Hohenester S, Oude-Elferink RP, Beuers U (2009) Primary biliary cirrhosis. Semin Immunopathol 31(3):283\u2013307","journal-title":"Semin Immunopathol"},{"issue":"5","key":"513_CR2","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.jhep.2011.10.025","volume":"56","author":"K Boonstra","year":"2012","unstructured":"Boonstra K, Beuers U, Ponsioen CY (2012) Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a\u00a0systematic review. J\u00a0Hepatol 56(5):1181\u20131188","journal-title":"J Hepatol"},{"issue":"4","key":"513_CR3","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1055\/s-0035-1567831","volume":"35","author":"AF Gulamhusein","year":"2015","unstructured":"Gulamhusein AF, Juran BD, Lazaridis KN (2015) Genome-wide association studies in primary Biliary cirrhosis. Semin Liver Dis 35(4):392\u2013401","journal-title":"Semin Liver Dis"},{"issue":"4","key":"513_CR4","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1016\/j.jhep.2004.08.002","volume":"41","author":"D Vergani","year":"2004","unstructured":"Vergani D et\u00a0al (2004) Liver autoimmune serology: a\u00a0consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J\u00a0Hepatol 41(4):677\u2013683","journal-title":"J Hepatol"},{"issue":"4","key":"513_CR5","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1002\/hep.23810","volume":"52","author":"U Beuers","year":"2010","unstructured":"Beuers U et\u00a0al (2010) The biliary HCO(3)(\u2212) umbrella: a\u00a0unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies. Hepatology 52(4):1489\u20131496","journal-title":"Hepatology"},{"issue":"1","key":"513_CR6","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/hep.24691","volume":"55","author":"S Hohenester","year":"2012","unstructured":"Hohenester S et al (2012) A biliary HCO3\u2212 umbrella constitutes a\u00a0protective mechanism against bile acid-induced injury in human cholangiocytes. Hepatology 55(1):173\u2013183","journal-title":"Hepatology"},{"issue":"3","key":"513_CR7","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1055\/s-0034-1383727","volume":"34","author":"A Lleo","year":"2014","unstructured":"Lleo A et\u00a0al (2014) Role of cholangiocytes in primary biliary cirrhosis. Semin Liver Dis 34(3):273\u2013284","journal-title":"Semin Liver Dis"},{"issue":"3","key":"513_CR8","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1159\/000371904","volume":"33","author":"M Trauner","year":"2015","unstructured":"Trauner M et al (2015) Potential of nor-ursodeoxycholic acid in cholestatic and metabolic disorders. Dig Dis 33(3):433\u2013439","journal-title":"Dig Dis"},{"issue":"1","key":"513_CR9","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"GM Hirschfield","year":"2017","unstructured":"Hirschfield GM et\u00a0al (2017) EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J\u00a0Hepatol 67(1):145\u2013172","journal-title":"J Hepatol"},{"issue":"6","key":"513_CR10","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.jhep.2017.07.022","volume":"67","author":"TH Karlsen","year":"2017","unstructured":"Karlsen TH et\u00a0al (2017) Primary sclerosing cholangitis\u2014a\u00a0comprehensive review. J\u00a0Hepatol 67(6):1298\u20131323","journal-title":"J Hepatol"},{"issue":"10139","key":"513_CR11","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1016\/S0140-6736(18)30300-3","volume":"391","author":"JK Dyson","year":"2018","unstructured":"Dyson JK et\u00a0al (2018) Primary sclerosing cholangitis. Lancet 391(10139):2547\u20132559","journal-title":"Lancet"},{"issue":"2","key":"513_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1097\/MEG.0000000000000532","volume":"28","author":"RE Rossi","year":"2016","unstructured":"Rossi RE, Conte D, Massironi S (2016) Primary sclerosing cholangitis associated with inflammatory bowel disease: an update. Eur J Gastroenterol Hepatol 28(2):123\u2013131","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"8","key":"513_CR13","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.cgh.2008.03.016","volume":"6","author":"A Bergquist","year":"2008","unstructured":"Bergquist A et al (2008) Increased risk of primary sclerosing cholangitis and ulcerative colitis in first-degree relatives of patients with primary sclerosing cholangitis. Clin Gastroenterol Hepatol 6(8):939\u2013943","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"513_CR14","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/lt.22161","volume":"16","author":"CL Bowlus","year":"2010","unstructured":"Bowlus CL et\u00a0al (2010) Primary sclerosing cholangitis in genetically diverse populations listed for liver transplantation: unique clinical and human leukocyte antigen associations. Liver Transpl 16(11):1324\u20131330","journal-title":"Liver Transpl"},{"issue":"Suppl 2","key":"513_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1159\/000440830","volume":"33","author":"U Beuers","year":"2015","unstructured":"Beuers U et al (2015) IgG4-associated cholangitis\u2014a mimic of PSC. Dig Dis 33(Suppl 2):176\u2013180","journal-title":"Dig Dis"},{"issue":"6","key":"513_CR16","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1056\/NEJMra1104650","volume":"366","author":"JH Stone","year":"2012","unstructured":"Stone JH, Zen Y, Deshpande V (2012) IgG4-related disease. N\u00a0Engl J Med 366(6):539\u2013551","journal-title":"N Engl J Med"},{"issue":"3","key":"513_CR17","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1053\/j.gastro.2007.12.009","volume":"134","author":"A Ghazale","year":"2008","unstructured":"Ghazale A et al (2008) Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology 134(3):706\u2013715","journal-title":"Gastroenterology"},{"issue":"6","key":"513_CR18","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1097\/MPA.0b013e3182480c99","volume":"41","author":"A Kanno","year":"2012","unstructured":"Kanno A et\u00a0al (2012) Nationwide epidemiological survey of autoimmune pancreatitis in Japan. Pancreas 41(6):835\u2013839","journal-title":"Pancreas"},{"issue":"6","key":"513_CR19","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1002\/hep.26232","volume":"57","author":"LJ Maillette de Buy Wenniger","year":"2013","unstructured":"Maillette de Buy Wenniger LJ et al (2013) Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis. Hepatology 57(6):2390\u20132398","journal-title":"Hepatology"},{"issue":"4","key":"513_CR20","first-page":"728","volume":"67","author":"LM Hubers","year":"2018","unstructured":"Hubers LM et al (2018) Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. Gut 67(4):728\u2013735","journal-title":"Gut"},{"issue":"2","key":"513_CR21","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","volume":"51","author":"European Association for the Study of the Liver","year":"2009","unstructured":"European Association for the Study of the Liver (2009) EASL clinical practice guidelines: management of cholestatic liver diseases. J\u00a0Hepatol 51(2):237\u2013267","journal-title":"J Hepatol"},{"issue":"3","key":"513_CR22","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1055\/s-0034-1383734","volume":"34","author":"A Floreani","year":"2014","unstructured":"Floreani A, Franceschet I, Cazzagon N (2014) Primary biliary cirrhosis: overlaps with other autoimmune disorders. Semin Liver Dis 34(3):352\u2013360","journal-title":"Semin Liver Dis"},{"issue":"5","key":"513_CR23","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1002\/hep.21405","volume":"44","author":"R Abdalian","year":"2006","unstructured":"Abdalian R, Heathcote EJ (2006) Sclerosing cholangitis: a\u00a0focus on secondary causes. Hepatology 44(5):1063\u20131074","journal-title":"Hepatology"},{"issue":"4","key":"513_CR24","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/hep.26999","volume":"60","author":"LJ Buy Wenniger de","year":"2014","unstructured":"de Buy Wenniger LJ, Culver EL, Beuers U (2014) Exposure to occupational antigens might predispose to IgG4-related disease. Hepatology 60(4):1453\u20131454","journal-title":"Hepatology"},{"issue":"2","key":"513_CR25","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1002\/hep.28568","volume":"64","author":"ME Doorenspleet","year":"2016","unstructured":"Doorenspleet ME et al (2016) Immunoglobulin G4(+) B\u2011cell receptor clones distinguish immunoglobulin G 4\u2011related disease from primary sclerosing cholangitis and biliary\/pancreatic malignancies. Hepatology 64(2):501\u2013507","journal-title":"Hepatology"},{"issue":"7","key":"513_CR26","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1038\/ajg.2014.131","volume":"109","author":"NP Chalasani","year":"2014","unstructured":"Chalasani NP et al (2014) ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 109(7):950\u2013966 (quiz 967)","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"513_CR27","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/0895-4356(93)90101-6","volume":"46","author":"G Danan","year":"1993","unstructured":"Danan G, Benichou C (1993) Causality assessment of adverse reactions to drugs\u2014I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J\u00a0Clin Epidemiol 46(11):1323\u20131330","journal-title":"J Clin Epidemiol"},{"issue":"2","key":"513_CR28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1093\/gastro\/gox012","volume":"5","author":"B Procopet","year":"2017","unstructured":"Procopet B, Berzigotti A (2017) Diagnosis of cirrhosis and portal hypertension: imaging, non-invasive markers of fibrosis and liver biopsy. Gastroenterol Rep (Oxf) 5(2):79\u201389","journal-title":"Gastroenterol. Rep. (Oxf)"},{"issue":"6","key":"513_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.jhep.2017.02.013","volume":"66","author":"L Aabakken","year":"2017","unstructured":"Aabakken L (2017) Role of endoscopy in primary sclerosing cholangitis: European Society of Gastrointestinal Endoscopy (ESGE) and European Association for the Study of the Liver (EASL) clinical guideline. J\u00a0Hepatol 66(6):1265\u20131281","journal-title":"J Hepatol"},{"issue":"1","key":"513_CR30","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cld.2015.08.005","volume":"20","author":"S Sarkar","year":"2016","unstructured":"Sarkar S, Bowlus CL (2016) Primary sclerosing cholangitis: multiple phenotypes, multiple approaches. Clin Liver Dis 20(1):67\u201377","journal-title":"Clin Liver Dis"},{"issue":"3","key":"513_CR31","doi-asserted-by":"publisher","first-page":"536","DOI":"10.2214\/AJR.12.10360","volume":"202","author":"A Tokala","year":"2014","unstructured":"Tokala A et al (2014) Comparative MRI analysis of morphologic patterns of bile duct disease in IgG4-related systemic disease versus primary sclerosing cholangitis. AJR Am J Roentgenol 202(3):536\u2013543","journal-title":"AJR Am. J. Roentgenol."},{"issue":"5","key":"513_CR32","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1002\/hep.21828","volume":"46","author":"PS Leung","year":"2007","unstructured":"Leung PS et\u00a0al (2007) Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology 46(5):1436\u20131442","journal-title":"Hepatology"},{"issue":"2","key":"513_CR33","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0168-8278(00)80061-6","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo P et\u00a0al (2000) Serum autoantibodies in patients with primary sclerosing cholangitis. J\u00a0Hepatol 32(2):182\u2013187","journal-title":"J Hepatol"},{"issue":"3","key":"513_CR34","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/hep.24487","volume":"54","author":"AM Oseini","year":"2011","unstructured":"Oseini AM et al (2011) Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology 54(3):940\u2013948","journal-title":"Hepatology"},{"issue":"5","key":"513_CR35","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1002\/hep.26977","volume":"59","author":"K Boonstra","year":"2014","unstructured":"Boonstra K et al (2014) Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-associated cholangitis from primary sclerosing cholangitis. Hepatology 59(5):1954\u20131963","journal-title":"Hepatology"},{"issue":"4","key":"513_CR36","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1016\/j.cgh.2005.10.007","volume":"4","author":"AE Berstad","year":"2006","unstructured":"Berstad AE et\u00a0al (2006) Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clin Gastroenterol Hepatol 4(4):514\u2013520","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"513_CR37","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1097\/01.mpa.0000202941.85955.07","volume":"32","author":"T Nakazawa","year":"2006","unstructured":"Nakazawa T et\u00a0al (2006) Schematic classification of sclerosing cholangitis with autoimmune pancreatitis by cholangiography. Pancreas 32(2):229","journal-title":"Pancreas"},{"issue":"5","key":"513_CR38","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1148\/rg.315105735","volume":"31","author":"PA Vlachou","year":"2011","unstructured":"Vlachou PA et al (2011) IgG4-related sclerosing disease: autoimmune pancreatitis and extrapancreatic manifestations. Radiographics 31(5):1379\u20131402","journal-title":"Radiographics"},{"issue":"2","key":"513_CR39","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/BF00432479","volume":"379","author":"J Ludwig","year":"1978","unstructured":"Ludwig J, Dickson ER, McDonald GS (1978) Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis). Virchows Arch A Pathol Anat Histol 379(2):103\u2013112","journal-title":"Virchows Arch A Pathol Anat Histol"},{"issue":"Suppl 4","key":"513_CR40","first-page":"106","volume":"59","author":"PJ Scheuer","year":"1983","unstructured":"Scheuer PJ (1983) Primary biliary cirrhosis: diagnosis, pathology and pathogenesis. Postgrad Med\u00a0J 59(Suppl 4):106\u2013115","journal-title":"Postgrad Med J"},{"issue":"9","key":"513_CR41","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1038\/modpathol.2012.72","volume":"25","author":"V Deshpande","year":"2012","unstructured":"Deshpande V et al (2012) Consensus statement on the pathology of IgG4-related disease. Mod Pathol 25(9):1181\u20131192","journal-title":"Mod Pathol"},{"issue":"3","key":"513_CR42","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1053\/j.gastro.2005.08.052","volume":"130","author":"RP Oude Elferink","year":"2006","unstructured":"Oude Elferink RP, Paulusma CC, Groen AK (2006) Hepatocanalicular transport defects: pathophysiologic mechanisms of rare diseases. Gastroenterology 130(3):908\u2013925","journal-title":"Gastroenterology"},{"issue":"4","key":"513_CR43","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M Prince","year":"2002","unstructured":"Prince M et al (2002) Survival and symptom progression in a\u00a0geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years. Gastroenterology 123(4):1044\u20131051","journal-title":"Gastroenterology"},{"issue":"1","key":"513_CR44","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jhep.2012.02.014","volume":"57","author":"K Dilger","year":"2012","unstructured":"Dilger K et\u00a0al (2012) Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J\u00a0Hepatol 57(1):133\u2013140","journal-title":"J Hepatol"},{"issue":"6","key":"513_CR45","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/ncpgasthep0521","volume":"3","author":"U Beuers","year":"2006","unstructured":"Beuers U (2006) Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis. Nat Clin Pract Gastroenterol Hepatol 3(6):318\u2013328","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"issue":"6","key":"513_CR46","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1053\/jhep.2000.20240","volume":"32","author":"C Corpechot","year":"2000","unstructured":"Corpechot C et\u00a0al (2000) The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 32(6):1196\u20131199","journal-title":"Hepatology"},{"issue":"2","key":"513_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","volume":"128","author":"C Corpechot","year":"2005","unstructured":"Corpechot C et\u00a0al (2005) The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 128(2):297\u2013303","journal-title":"Gastroenterology"},{"issue":"1 Suppl","key":"513_CR48","doi-asserted-by":"publisher","first-page":"S25","DOI":"10.1016\/j.jhep.2015.02.023","volume":"62","author":"U Beuers","year":"2015","unstructured":"Beuers U et\u00a0al (2015) New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J\u00a0Hepatol 62(1 Suppl):S25\u2013S37","journal-title":"J Hepatol"},{"issue":"4","key":"513_CR49","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1053\/j.gastro.2014.12.005","volume":"148","author":"GM Hirschfield","year":"2015","unstructured":"Hirschfield GM et\u00a0al (2015) Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 148(4):751\u2013761.e8","journal-title":"Gastroenterology"},{"key":"513_CR50","doi-asserted-by":"publisher","first-page":"89","DOI":"10.2147\/HMER.S91709","volume":"8","author":"CL Bowlus","year":"2016","unstructured":"Bowlus CL (2016) Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection. Hepat Med 8:89\u201395","journal-title":"Hepat Med"},{"issue":"3","key":"513_CR51","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/ajg.2015.20","volume":"110","author":"K Hosonuma","year":"2015","unstructured":"Hosonuma K et al (2015) A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol 110(3):423\u2013431","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"513_CR52","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/hep.26565","volume":"58","author":"K Boonstra","year":"2013","unstructured":"Boonstra K et al (2013) Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology 58(6):2045\u20132055","journal-title":"Hepatology"},{"issue":"3","key":"513_CR53","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1002\/hep.23082","volume":"50","author":"KD Lindor","year":"2009","unstructured":"Lindor KD et al (2009) High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 50(3):808\u2013814","journal-title":"Hepatology"},{"issue":"1","key":"513_CR54","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/jhbp.50","volume":"21","author":"A Tanaka","year":"2014","unstructured":"Tanaka A et al (2014) Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J\u00a0Hepatobiliary Pancreat Sci 21(1):43\u201350","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"7","key":"513_CR55","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1002\/art.39132","volume":"67","author":"A Khosroshahi","year":"2015","unstructured":"Khosroshahi A et al (2015) International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 67(7):1688\u20131699","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"513_CR56","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/MPA.0000000000000044","volume":"43","author":"J Buijs","year":"2014","unstructured":"Buijs J et al (2014) Comparable efficacy of low- versus high-dose induction corticosteroid treatment in autoimmune pancreatitis. Pancreas 43(2):261\u2013267","journal-title":"Pancreas"},{"issue":"6","key":"513_CR57","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1136\/annrheumdis-2014-206605","volume":"74","author":"MN Carruthers","year":"2015","unstructured":"Carruthers MN et al (2015) Rituximab for IgG4-related disease: a\u00a0prospective, open-label trial. Ann Rheum Dis 74(6):1171\u20131177","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"513_CR58","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1136\/gut.50.3.436","volume":"50","author":"MI Prince","year":"2002","unstructured":"Prince MI, Burt AD, Jones DE (2002) Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis. Gut 50(3):436\u2013439","journal-title":"Gut"},{"issue":"6","key":"513_CR59","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","volume":"99","author":"A Pares","year":"2004","unstructured":"Pares A et\u00a0al (2004) Extracorporeal albumin dialysis: a\u00a0procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis. Am J Gastroenterol 99(6):1105\u20131110","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"513_CR60","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1016\/j.jhep.2006.08.008","volume":"45","author":"T Pusl","year":"2006","unstructured":"Pusl T et\u00a0al (2006) Plasma separation and anion adsorption transiently relieve intractable pruritus in primary biliary cirrhosis. J\u00a0Hepatol 45(6):887\u2013891","journal-title":"J Hepatol"},{"issue":"1","key":"513_CR61","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/hep.21271","volume":"44","author":"U Beuers","year":"2006","unstructured":"Beuers U, Gerken G, Pusl T (2006) Biliary drainage transiently relieves intractable pruritus in primary biliary cirrhosis. Hepatology 44(1):280\u2013281","journal-title":"Hepatology"},{"issue":"2","key":"513_CR62","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hep.510290229","volume":"29","author":"CR Gross","year":"1999","unstructured":"Gross CR et\u00a0al (1999) Quality of life before and after liver transplantation for cholestatic liver disease. Hepatology 29(2):356\u2013364","journal-title":"Hepatology"},{"issue":"Suppl 2: p","key":"513_CR63","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1159\/000440757","volume":"33","author":"L Jopson","year":"2015","unstructured":"Jopson L, Jones DE (2015) Fatigue in Primary Biliary Cirrhosis: Prevalence, Pathogenesis and Management. Dig Dis 33(Suppl 2: p):109\u2013114","journal-title":"Dig Dis"}],"container-title":["Der Radiologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-019-0513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00117-019-0513-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-019-0513-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,14]],"date-time":"2020-03-14T00:27:32Z","timestamp":1584145652000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00117-019-0513-x"}},"subtitle":["Diagnostische und therapeutische Herausforderungen"],"short-title":[],"issued":{"date-parts":[[2019,3,15]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["513"],"URL":"https:\/\/doi.org\/10.1007\/s00117-019-0513-x","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,15]]},"assertion":[{"value":"15 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"T.\u00a0Herta gibt an, dass kein Interessenkonflikt besteht. U.\u00a0Beuers: Vortragshonorare von Abbvie, Falk Foundation, Gilead, Intercept, Novartis, Roche, Shire, Zambon. Beratungshonorare von Intercept, Novartis. Studienunterst\u00fctzung (\u201einvestigator-initiated\u201c) von Dr. Falk, Intercept. Forschungsunterst\u00fctzung von deutschen (DCCV), norwegischen, amerikanischen und s\u00fcdafrikanischen PSC-Patientenstiftungen, Maag-Lever-Darm-Stichting Nederland und EU-Projekt LIVERHOPE.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}